PDF(Pubmed)
Abstract：
OBJECTIVE: To assess the association between pancreatic enzyme replacement therapy (PERT) and resource utilization among patients with chronic pancreatitis (CP) in a large Midwestern US healthcare system.
METHODS: This retrospective cohort study used electronic medical record data. Eligible patients (N = 2445) were aged ≥18 years and diagnosed with non-cystic fibrosis CP between January 2005 and December 2018, with ≥6 months\' follow-up; study initiation was first encounter with the healthcare system. Patients in the PERT group were prescribed PERT at ≥1 encounter; patients in the non-PERT group were not prescribed PERT at any encounter.
RESULTS: In total, 62,899 encounters were reviewed (PERT, n = 22,935; non-PERT, n = 39,964). More patients in the PERT group were younger, male, White, married/partnered and with private insurance than those in the non-PERT group. They also received longer care and had more overall encounters, fewer outpatient and day surgery/24-hour observation encounters, and more inpatient encounters. Emergency room encounters were similar between groups. Average cost by encounter was similar between groups ($225 and $213, respectively).
CONCLUSIONS: Despite similar average costs per encounter, the groups had very different encounter types. More inferential research on PERT use among patients with CP is needed, particularly regarding resource utilization and long-term outcomes.
METHODS: This retrospective cohort study used electronic medical record data. Eligible patients (N = 2445) were aged ≥18 years and diagnosed with non-cystic fibrosis CP between January 2005 and December 2018, with ≥6 months\' follow-up; study initiation was first encounter with the healthcare system. Patients in the PERT group were prescribed PERT at ≥1 encounter; patients in the non-PERT group were not prescribed PERT at any encounter.
RESULTS: In total, 62,899 encounters were reviewed (PERT, n = 22,935; non-PERT, n = 39,964). More patients in the PERT group were younger, male, White, married/partnered and with private insurance than those in the non-PERT group. They also received longer care and had more overall encounters, fewer outpatient and day surgery/24-hour observation encounters, and more inpatient encounters. Emergency room encounters were similar between groups. Average cost by encounter was similar between groups ($225 and $213, respectively).
CONCLUSIONS: Despite similar average costs per encounter, the groups had very different encounter types. More inferential research on PERT use among patients with CP is needed, particularly regarding resource utilization and long-term outcomes.
摘要：
目的：评估美国中西部大型医疗系统中慢性胰腺炎（CP）患者胰酶替代疗法（PERT）与资源利用之间的关系。
方法：本回顾性队列研究使用电子病历数据。符合条件的患者（N=2445）年龄≥18岁，在2005年1月至2018年12月期间诊断为非囊性纤维化CP，随访时间≥6个月；研究开始是首次与医疗保健系统接触。PERT组患者在≥1次相遇时给予PERT；非PERT组患者在任何相遇时都不给予PERT。
结果：总计，审查了62,899次相遇(PERT，n=22,935；非PERT，n=39,964）。PERT组的患者更年轻，男性,白色,与非PERT组的人相比，已婚/伴侣和私人保险。他们还接受了更长时间的护理，并有更多的整体遭遇，减少门诊和日间手术/24小时观察，和更多的住院经历。两组之间的急诊室遭遇相似。两组之间的平均相遇成本相似（分别为$225和$213）。
结论：尽管每次遭遇的平均成本相似，这些群体有非常不同的相遇类型。需要更多关于CP患者使用PERT的推理研究，特别是关于资源利用和长期成果。
方法：本回顾性队列研究使用电子病历数据。符合条件的患者（N=2445）年龄≥18岁，在2005年1月至2018年12月期间诊断为非囊性纤维化CP，随访时间≥6个月；研究开始是首次与医疗保健系统接触。PERT组患者在≥1次相遇时给予PERT；非PERT组患者在任何相遇时都不给予PERT。
结果：总计，审查了62,899次相遇(PERT，n=22,935；非PERT，n=39,964）。PERT组的患者更年轻，男性,白色,与非PERT组的人相比，已婚/伴侣和私人保险。他们还接受了更长时间的护理，并有更多的整体遭遇，减少门诊和日间手术/24小时观察，和更多的住院经历。两组之间的急诊室遭遇相似。两组之间的平均相遇成本相似（分别为$225和$213）。
结论：尽管每次遭遇的平均成本相似，这些群体有非常不同的相遇类型。需要更多关于CP患者使用PERT的推理研究，特别是关于资源利用和长期成果。
